Schizophrenia
Conditions
Keywords
Schizophrenia, Switching, Early stage, Risperidone, Aripirazole
Brief summary
Switching from Risperidone to Aripiprazole in early stage of pharmacotherapy will demonstrate the same efficacy as compared to risperidone continuation treatment in the treatment of schizophrenia.
Detailed description
It has been thought that D2 Blocking agent is necessary in acute as well as maintenance phase of pharmacological treatment of patients with schizophrenia. However, this classical strategy produces long term adverse events of drug such as TD, osteoporosis and some metabolic syndrome. To overcome these adverse events, new strategy for pharmacological treatment is needed.
Interventions
DRUGRispridoen and Aripiprazole
Start with risperidone and switch it to aripiprazole. Flexible dose
DRUGRisperidne
Start with risperidne and keep it through the end of study. Risperidne:flexible dose
DRUGAbilify
Start with abilify and keep it through the end of study
Sponsors
Inje University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* Schizophrenia, DSM-IV * Acute phase
Exclusion criteria
* Refractory Schizophrenia * Substance Abuse * High risk for suicide
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SANS(Scale for the Assessment of Negative Symptoms) | 12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| SARS(Simpson-Angus Rating Scale) | 12 weeks |
| Drug Attitude Inventory | 12 weeks |
| Side effect checklist | 12 weeks |
Countries
South Korea
Contacts
Primary ContactEun-A Lee, MS
Outcome results
None listed